The national and subnational burden of Hodgkin Lymphoma (HL) in Italy from 1990 to 2023: results from the Global Burden of Disease Study 2023.
Creators
- 1. Department of Medical Sciences, University of Torino, Torino, Italy.
- 2. Department of Imaging, AOU Città della Salute e della Scienza di Torino, Torino, Italy.
- 3. Clinical Epidemiology and Public Health Research Unit, Burlo Garofolo Institute for Maternal and Child Health, Trieste, Italy.
- 4. Institute for Research and Innovative Technologies, Area Science Park, Trieste, Italy.
- 5. Department of Health Sciences (DISSAL), University of Genoa, Genova, Italy.
- 6. University of Genoa
- 7. Department of Nuclear Medicine, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
- 8. Scientific Institute for Research, Hospitalization and Healthcare
- 9. Institute for Cancer Research, Prevention and Clinical Network, Florence, Italy.
- 10. The World Academy of Sciences UNESCO, Trieste, Italy.
- 11. Shaanxi University of Technology, Hanzhong, China.
- 12. Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
- 13. University of Milan
- 14. Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
- 15. Multidisciplinary Department of Medical-Surgical and Dental Specialties, University of Campania Luigi Vanvitelli, Naples, Italy.
- 16. Saveetha Dental College and Hospitals, Saveetha University, Chennai, India.
Description
Hodgkin Lymphoma (HL) is a relatively rare oncohematological neoplasm. This study investigates the burden of HL and its temporal trends from 1990 to 2023, at the Italian national and subnational level (21 regions).
We used the Global Burden of Disease Study 2023 estimates to describe the HL age-standardized incidence (ASIR), mortality (ASMR), years lived with disability (ASYLD), years of life lost (ASYLL), disability-adjusted life years (ASDR) rates, the related 1990-2023 crude all-ages and age-standardized annual rate of changes (ARC), as well as the age-standardized mortality-to-incidence ratio (MIR). Finally, the national estimates for HL were compared to those for the GBD Global and High-middle Socio-Demographic Index (SDI) countries.
In 2023 at the Italian national level, there were 1750 HL new cases, 430 deaths and 10,850 Disability-Adjusted Life Years (DALYs), the majority of which came from YLLs (91.0%). The 1990-2023 ARC for ASIR had a notable decline for both sexes (-0.26; 95% Uncertainty Interval [UI] -0.43 to -0.03). The ARC for ASMR (-0.59; -0.66 to -0.51) and ASDR (-0.64; -0.70 to -0.57) remarkably declined for both sexes; the MIR almost halved over time, from 25.9 to 14.3. At the subnational level, the ASIR significantly decreased in eleven regions, being stable in the other ten. The ASMR and ASDR showed a marked decline in all 21 regions.
The HL age-standardized deaths and DALYs rates significantly improved over time in Italy, while ASIR was twofold and threefold than that measured for GBD High-middle SDI countries and globally, respectively. Comparing the national estimates to those for the High-middle SDI region, the ARC for YLDs, YLLs and DALYs showed a comparable, favorable trend. Some geographical differences emerged among the Italian subnational estimates, even in the absence of serious local anomalies.
No funding was received for this study. This work was supported by the Italian Ministry of Health, through a contribution given to the Institute for Maternal and Child Health - IRCCS Burlo Garofolo, Trieste - Italy.
© 2025 Published by Elsevier Ltd.
Open Access
Licence Attribution (CC BY)
Publisher Website
Access full text
Publication Details
Journal article
Persistent Identifiers
References
Eichenauer . Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, ...
Read more
Harris . The many faces of Hodgkin\u2019s disease around the world: what have we...
Read more
Glaser . The epidemiology of Hodgkin\u2019s disease, Baillieres Clin Haematol. 1...
Read more
Ansell . Hodgkin lymphoma: a 2020 update on diagnosis, risk-stratification, and ...
Read more
Stevens . Guidelines for accurate and transparent health estimates reporting: th...
Read more
Showing first 5 of 39 references.